Tapering Schedule for Discontinuing Trazodone and Clonazepam
Taper the trazodone first over 2-4 weeks, then begin a slow clonazepam taper using a hyperbolic reduction schedule of 25% every 1-2 weeks, which may take several months to complete safely.
Sequencing: Which Medication to Stop First
The evidence strongly supports tapering trazodone before clonazepam. While the provided guidelines primarily address opioid-benzodiazepine combinations, the principle applies here: benzodiazepine withdrawal carries greater risks than trazodone discontinuation 1, 2. Benzodiazepine withdrawal can cause seizures, delirium tremens, hallucinations, and in rare cases death, whereas trazodone withdrawal is generally milder 1.
Trazodone Discontinuation
Taper trazodone 150 mg over 2-4 weeks:
- Week 1-2: Reduce to 100 mg daily
- Week 3: Reduce to 50 mg daily
- Week 4: Discontinue
Trazodone has a short half-life and can produce withdrawal symptoms including anxiety, insomnia, and noradrenergic rebound 3. The evidence suggests tapering "at a very slow rate" due to serotonergic effects 3, though specific schedules are not well-established. A 2-4 week taper represents a cautious approach for this moderate dose.
Clonazepam Discontinuation
Begin clonazepam taper only after successfully discontinuing trazodone. This prevents compounding withdrawal symptoms and allows clear attribution of any emerging symptoms.
Tapering Protocol
Use a hyperbolic (proportionate) reduction schedule rather than linear reductions 1, 2, 4, 5. The relationship between benzodiazepine dose and GABA-A receptor occupancy is hyperbolic—linear reductions produce increasingly severe withdrawal effects as doses decrease 4.
For clonazepam 0.5-1 mg daily (patient's PRN range):
- Reduce by 25% of the current dose every 1-2 weeks 1, 2
- Starting from 1 mg daily (assuming maximum PRN use):
- Weeks 1-2: 0.75 mg daily
- Weeks 3-4: 0.56 mg daily (approximately 0.5 mg)
- Weeks 5-6: 0.375 mg daily
- Weeks 7-8: 0.25 mg daily
- Weeks 9-10: 0.125 mg daily
- Weeks 11-12: Discontinue
Critical point: The final doses must be very small—as little as 0.2 mg or less 4—so the last step to zero is not larger than previously tolerated reductions. This requires liquid formulations or compounded preparations 4, 5.
Alternative Evidence-Based Approach
One high-quality study of long-term clonazepam users (mean dose 2.7 mg/day) successfully used 6:
- 0.5 mg reduction every 2 weeks until reaching 1 mg/day
- Then 0.25 mg reduction per week
This achieved 68.9% medication-free at 4 months with mostly mild withdrawal symptoms 6. However, this represents a more aggressive linear taper that may not be optimal for minimizing withdrawal.
Monitoring and Management
Follow up at least monthly during tapering 7. More frequent contact (weekly or biweekly) is advisable during clonazepam taper.
Withdrawal Symptoms to Monitor
Clonazepam withdrawal signs 8:
- Anxiety, insomnia, panic attacks
- Tremor, muscle stiffness, twitching
- Gastrointestinal symptoms (nausea, vomiting, diarrhea)
- Perceptual changes (photophobia, hyperacusis)
- Severe: Seizures, hallucinations, delirium, catatonia
If withdrawal symptoms emerge:
- Slow the taper rate or pause 7
- Return to previous tolerated dose if necessary 7, 5
- Do not proceed until symptoms resolve
- Consider extending taper over several additional months
Adjunctive Support
Strongly recommended 1, 2, 9, 5:
- Cognitive behavioral therapy (CBT) increases tapering success rates 1
- Patient education materials and self-help information 9
- Peer support resources 5
- Regular clinician contact via phone, telehealth, or in-person 7
Critical Safety Considerations
Never abruptly discontinue clonazepam 8. Abrupt cessation can precipitate life-threatening seizures and severe withdrawal reactions.
Avoid rapid tapering 7. Faster tapers are associated with increased risk of overdose (adjusted incidence rate ratio 1.09 per 10% monthly dose increase) and mental health crisis (adjusted incidence rate ratio 1.18) 7.
Screen for anxiety and depression throughout the taper 7, 8. If anxiety worsens, consider evidence-based alternatives like CBT or antidepressants rather than reversing the taper 1, 2.
Protracted withdrawal syndrome can persist for weeks to over 12 months after benzodiazepine discontinuation, characterized by anxiety, insomnia, cognitive impairment, and motor symptoms 8. Distinguish this from symptom recurrence.
Practical Implementation
Obtain informed consent before beginning 5. Discuss risks of continuing versus discontinuing, expected timeline, and possibility of withdrawal symptoms.
Use shared decision-making 7, 5. Patient agreement is a key component of successful tapers 7.
For very low doses: Obtain liquid clonazepam or compounded formulations to enable precise small reductions 4, 5. Standard tablets cannot be accurately divided below 0.25 mg.
Total expected duration: 2-4 weeks for trazodone, then 3-6 months minimum for clonazepam, potentially extending to 12+ months if withdrawal symptoms require slower tapering.